EUVIMEDEUVIMED entdecken
Crossref

Design, synthesis and evaluation of trofinetide prodrug based on diketopiperazine strategy

Xue Feng, Yuanzhen Dong, Chen Guo, Jianguang Lu, Zhiru Xu, Jing Bian, Wenjing Peng, Tao Luo, Jun Feng

Bioorganic & Medicinal Chemistry · 2026-06 · 137 · 118633

DOI: 10.1016/j.bmc.2026.118633 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry, 2026-06. Verfasst von Xue Feng und 8 weiteren Autor:innen. Beteiligte Einrichtung: China State Institute of Pharmaceutical Industry, 201203 Shanghai, China. Hauptthemen laut MEDLINE: Prodrugs, Diketopiperazines, Drug Design. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Trofinetide is the only drug approved worldwide for the treatment of Rett syndrome, a rare pediatric disease. However, its extremely short half-life, large oral dose, high incidence of gastrointestinal adverse reactions, and consequently high treatment costs pose formidable clinical and economic challenges. To address these issues, we employed a diketopiperazine strategy to design a novel class of trofinetide prodrugs, aiming to alter the administration route and optimize its pharmacokinetic properties. Through the determination of solubility and in vitro conversion half-life, and based on the established screening criteria, TFD 10 was selected from the series of qualified compounds as a representative for pharmacokinetic evaluation. TFD 10 exhibited efficient conversion to trofinetide both in vitro and in vivo. Compared to oral administration of trofinetide, subcutaneous injection of TFD 10 markedly prolonged the half-life (6-fold) and substantially increased systemic exposure (40-fold), successfully achieving the design objectives. This study validates the feasibility of this strategy, and TFD 10, as a proof-of-concept lead compound, demonstrates significant potential for further development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsDiketopiperazinesDrug DesignAnimalsHumansMolecular StructureMiceHalf-LifeRatsMale

Stichwörter der Autor:innen

DiketopiperazinePharmacokineticsProdrugTrofinetide

Substanzen

ProdrugsDiketopiperazines

Autor:innen und Institutionen

  • China State Institute of Pharmaceutical Industry, 201203 Shanghai, China.
  • China State Institute of Pharmaceutical Industry, 201203 Shanghai, China; Shanghai Duomirui Biotechnology Ltd., 201203 Shanghai, China.
  • School of Pharmaceutical Sciences, Shanghai Jiao Tong University, 200240 Shanghai, China.
  • National Key Laboratory of Lead Druggability Research, China State Institute of Pharmaceutical Industry Co. Ltd., 201203 Shanghai, China; Shanghai Professional and Technical Service Center for Biological Material Drug-a…
  • Shanghai Duomirui Biotechnology Ltd., 201203 Shanghai, China.
  • China State Institute of Pharmaceutical Industry, 201203 Shanghai, China. Electronic address: fengjdmr@163.com.

Zitieren

APA

Feng, X., Dong, Y., Guo, C., Lu, J., Xu, Z., Bian, J., Peng, W., Luo, T., & Feng, J. (2026). Design, synthesis and evaluation of trofinetide prodrug based on diketopiperazine strategy. Bioorganic & Medicinal Chemistry, 137, 118633. https://doi.org/10.1016/j.bmc.2026.118633

Vancouver

Feng X, Dong Y, Guo C, Lu J, Xu Z, Bian J, et al. Design, synthesis and evaluation of trofinetide prodrug based on diketopiperazine strategy. Bioorganic & Medicinal Chemistry. 2026;137:118633. doi:10.1016/j.bmc.2026.118633

BibTeX
@article{Feng2026,
  author = {Feng, Xue and Dong, Yuanzhen and Guo, Chen and Lu, Jianguang and Xu, Zhiru and Bian, Jing and Peng, Wenjing and Luo, Tao and Feng, Jun},
  title = {Design, synthesis and evaluation of trofinetide prodrug based on diketopiperazine strategy},
  journal = {Bioorganic & Medicinal Chemistry},
  year = {2026},
  volume = {137},
  pages = {118633},
  doi = {10.1016/j.bmc.2026.118633}
}
Kostenlos starten →